The 18q chromosome arm is frequently lost in advanced head and neck squamous cell carcinoma. Twenty-four microsatellite markers located on chromosome 18q were genotyped in 145 primary tumors and 10 cell lines in order to identify putative tumor suppressor genes implicated in tumor progression. Two different minimal common regions of loss (MCRL) were identified at 18q22 and 18q23 respectively. To refine and delineate boundaries of an homozygous deletion found in one cell line, 44 extra markers located at 18q22 were analysed and the homozygous deletion was precisely defined within a critical region of 4.9 Mb. Four known genes (CDH7, CDH19, DNAM-1, FLJ23594) located in this critical region and two EST clusters (Hs.96900, Hs.98628) were selected for further investigations. For these six genes, genomic structures were established, somatic mutations were screened in 20 HNSCC and 10 cell lines and transcription levels were determined in eight cell lines. No somatic mutations were found in any of the candidate genes analysed (57 coding exons). However, differential transcription levels were observed for CDH19 and Hs.96900 in head and neck cancer cell lines supporting their putative involvement through down regulation mechanisms in head and neck cancer progression.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is an important health problem worldwide with approximately 400 000 new cases each year. If small tumors are often curable, the outcome of advanced diseases has not dramatically improved in the past years. Understanding head and neck carcinogenesis through the use of new molecular technologies should provide sensitive tools to diagnose, treat and follow patients with head and neck tumors. Like most types of solid tumors, head and neck cancer is believed to arise after accumulation of genetic alterations resulting, at least partially, from chronic exposure of the upper aerodigestive tract to tobacco carcinogens. The most frequent genetic alterations observed in HNSCC tumors are chromosome losses leading to the inactivation of tumor suppressor genes (TSG).
We and others, have reported previously that chromosome arms 3p, 9p, 8p, 17p and 18q showed frequent loss of heterozygosity in HNSCC. Average percentages are up to 90% for 3p and 9p, 50% for 8p and 17p and 40% for 18q (Blons et al., 1999a; Califano et al., 1996; Nawroz et al., 1994) . To date, the targets of the deletions at 9p and 17p have been identified. Indeed p16 on 9p21 and TP53 on 17p21 demonstrated either promoter hypermethylation or mutations as a second hit of inactivation (Cabelguenne et al., 2000; ElNaggar et al., 1997) . Concerning chromosome 3p, several genes have been suspected and studied as TGFbRII (Garrigue-Antar et al., 1995) , OGG1 (Blons et al., 1999b) , and FHIT (Kisielewski et al., 1998; Mao et al., 1996) but their roles are still not ascertained. TSG implicated in HNSCC carcinogenesis and located on chromosomes 8p and 18q remain to be identified. The presence of LOH on 18q is of particular interest since it was related to tumor stage and prognosis (Pearlstein et al., 1998) . This correlation was also found in other types of tumors (i.e. breast, gallbladder, colon, prostate, and non-small-cell lung cancer), suggesting that inactivation of genes located at 18q could influence tumor progression (Adeyinka et al., 1999; Hidaka et al., 1999; Jen et al., 1994; Padalecki et al., 2000; Shiseki et al., 1996; Ueda et al., 1997) . Moreover, on prostate, colon and endometrial cancer, microcell-mediated chromosome 18 transfer into cell lines suppressed tumorigenicity (Padalecki et al., 2001; Tanaka et al., 1991; Yamada et al., 1995) . These works provided functional evidence for the presence of one or more TSGs on 18q. The identification of LOH at 18q by several groups in tumors or cell lines, allowed the identification of various regions of deletion depending on cancer type. Concerning HNSCC, three different common regions of loss were recently identified in cell lines (Takebayashi et al., 2000) . The first one is centered on marker D18S39 in band 18q21.1, the second one is a 15 Mb deletion bounded by D18S392 and D18S554 and the most telomeric one is centered around D18S70 but as yet, no gene alterations have been identified in HNSCC. Among them, the 18q21 region retained, initially, the attention as it co-locates the TSGs SMAD2, SMAD4 and DCC but mutation screenings in different types of cancers including HNSCC demonstrated very few mutations leading to the hypothesis of the existence of non-identified tumor suppressor genes on 18q (Kim et al., 1996; Riggins et al., 1997) . In the present study, high density allelotype was performed on chromosome 18 in a prospective series of 145 HNSCC and in a series of 10 head and neck cell lines. Twenty-nine polymorphic markers were screened on all tumors and cell lines series and 44 extra markers were analysed to delineate boundaries of a 4.9 Mb critical region homozygously deleted in the HTB43 cell line. This region was extensively analysed to identify new candidate genes and their putative genetic alterations in HNSCC tumors.
Results

Deletion map of 18q in HNSCC specimens and cell lines
One hundred and forty-five tumors and 10 cell lines were examined for loss of heterozygosity (LOH) using 29 microsatellite markers on chromosome 18. Five markers were localized at 18p and 24 at 18q. Fiftyseven tumors had deletions involving chromosome 18 (40%). Nineteen tumors demonstrated chromosome 18 monosomy, seven partial 18p loss with retention of 18q, 11 total 18q loss, 19 showed partial or interstitial deletion at 18q (Figure 1a ). There is a strong relationship between the loss of 18q and the stage of tumors since tumors of stage I and II demonstrated allelic losses at 18q in 23% of cases whereas tumors of stage III and IV demonstrated allelic losses in 50% of the cases (P=0.004). Concerning cell lines, all, except for CRL1628 and CRL1629, showed extended contiguous homozygosity at 18q from D18S1102 to D18S70 suggesting the loss of a large fragment of this chromosome arm. Moreover HTB43 showed homozygous deletion at D18S477, D18S979, GATA7g11, D18S1131, D18S1092, D18S61 (Figure 1b ) since these six contiguous markers failed to produce PCR amplifications. The absence of PCR products was ascertained by co-amplification experiments (Figure 2 ). Taken together these results suggested the existence of two non-overlapping regions of deletion at 18q in HNSCC. A distal minimal common region of loss MCRL1 spanning from D18S1161 to telomere was defined by telomeric partial deletions in three tumors. A more centromeric region (MCRL2), centered at 18q22 was defined by three interstitial deletions found in tumors and by one homozygous deletion found in HTB43 (Figure 1a,b) . Therefore it was decided to further characterize the proximal and distal borders of the homozygous deletion using HTB43 to allow unambiguous definition of the MCRL2.
Refining the MCRL2
To estimate the size of the MCRL2 region, genomic PCR analyses were performed with a total of 44 extra markers on HTB43 DNA. Results are shown in Figure  3 . All the markers tested between L10844 and IB2403 were found homozygously deleted and a region of interest of 4.9 Mb was defined according to the relative position of markers in Draft human genome browser database. Three non-overlapping contigs of sequence (ctg13116, ctg19081 and ctg15114), with a gap of estimated 400 Kb, were located in this region (genome. cse.ucsc.edu/goldenPath/apr2001Tracks.html).
Search for genetic alterations in known genes
Genes located in this minimal region of deletion were identified by searching through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov), the Ensembl genome server (http://www.ensembl.org/), the Draft human genome browser (http://genome.ucsc. edu/goldenPath/septTracks.html). Four known genes identified in the critical region, i.e. CDH7, CDH19, FLJ23594 and DNAM-1 ( Figure 3 ) were screened for somatically acquired mutations. Three are of special interest CDH7, CDH19 and DNAM-1 according to their roles as adhesion molecules. No amplification could be obtained for those four genes in HTB43 DNA confirming their location in the homozygously deleted region. For these genes, RT -PCR experiments were performed in eight head and neck cancer cell lines. Transcripts were retrieved for CDH19 in CCL17, but no PCR products were found for DNAM-1 CDH7 and FLJ23594 in any head and neck cancer cell lines tested. For these four candidate genes, all 35 coding exons were screened by dHPLC for point mutations in the series of 10 HNSCC cell lines and in 20 tumors demonstrating LOH at 18q. Tumor DNAs showing abnormal chromatogram profiles were sequenced and the following variations were detected in exons 3 (T159T/G477A), 5 (V228V/G684T), 11 (S576N/ A1727G, V675V/C1764T, D588D/C1848T) and in intron 10 (+20 C/T, +22 A/T) for CDH7; in exon 7 (V391M/G1310A) and 11 (P558P/G1810A and T565T/ A1831C) for CDH19, in exon 6 (E282E/G1054A) and 7 (G326S/G1127A) for DNAM-1 and in exon 2 (K82R/ A245G) and in intron 2 (+4 T/C) for FLJ23594. No somatic mutations were found in these four genes, all variations were retrieved in matched normal DNA and therefore corresponded to polymorphisms.
Search for genetic alterations in previously unknown genes
Within the ESTs assigned to the MCRL2 region, two clusters of ESTs were selected Hs.98628 and Hs.96900. In both cases, no amplifications were detected using HTB43 genomic DNA indicating their localization in the region of interest. For Hs.98628 nucleotide BLAST alignment demonstrated the existence of seven exons that code for a protein that produced significant alignment with phosphotyrosine-binding domain (IRS-1 type) and showed sequence homologies (57%/ 39AA) with p56 dok-2 Mus musculus protein (AAC95339). No transcription could be retrieved by RT -PCR for Hs.98628 in eight head and neck cancer cell lines. All translated sequence except for the first 84 bases could be assessed to mutation screening. One polymorphism was found in exon 3 (T38T/G114A), two polymorphisms in exon 6 (L197S/T590C, K204T/ A611C) and one in exon 7 (H236D/G707A).
Concerning Hs.96900, transcription levels demonstrated variability among cell lines. CRL1629 and CCL138 did not show any transcript for Hs.96900. To confirm this variation, co-amplifications were run using a new set of primers in Hs.96900 and the actin gene as a reference (Figure 4 ). These transcriptional level differences in cell lines pointed this gene as an interesting target and further analyses were undertaken. At the time the experiment was run, the complete cDNA related to Hs.96900 cluster had not been cloned and the sequence of the putative gene had to be determined. The alignment of the cDNA sequence with genomic sequence data allowed the identification of 10 exons. A total of six more exons were identified using SMART technology. The gene identified counts 16 exons and spans 40 kb on AC040896.2. There is an untranslated GC rich region of 127 bases before the most obvious ATG in the context of the Kozak's rules and an open reading frame of 454 amino acid residues. Multiple tissues of Northern blot were hybridized with a specific probe and all tested tissues but bone marrow revealed two transcripts of approximately 3.5 and 4 Kb due to two poly-adenylation signals as identified by two different groups of ESTs (data not shown). Analysis of the entire protein sequence showed the presence of a functionally characterized thioredoxin motif and similarities with calsequestrin. The entire gene sequence was analysed by dHPLC for mutation screening and four polymorphisms were found in non-coding regions of the gene, intron 2: T+34G, intron 6: T+35C, intron 8: T+67C, intron 9: 17 -18DTT.
Discussion
LOH at 18q occurs frequently in head and neck cancer and is associated with advanced stage tumors and worse survival. This study deals with the identification of a region of LOH on chromosome 18q, likely to contain putative genes involved in head and neck progression. The definition of the minimal lost region boundaries by genotyping makes it possible to focus the search for TSG in a definite region. Since it is an important step in the strategy of gene identification, the reliance in the determination of LOH is essential. LOH in tumor tissues can be influenced by the presence of contaminating normal cells in tumor fragments. In this study, the use of quantitative fluorescent genotyping and the comparison with the LOH status at 9p allowed controlled definition of lost regions in tumors, avoiding misinterpretation of allelic imbalances.
Most tumors presented large deletions often including the entire 18q but a subset of tumors with interstitial and partial deletions allowed the definition of two regions of loss at 18q. These two regions are in accordance with the 18q22 and 18q23 regions defined by Takebayashi et al. (2000) in HNSCC. They are also very similar to both regions recently defined in ovarian carcinoma (Lassus et al., 2001) . Although LOH could be no more than a random rearrangement in tumors and fine mapping has rarely led, by itself, to the identification of TSG, this work focused on the 18q22 region (MCRL2) because of the existence of a homozygous deletion in HTB43. It is interesting to note that three homozygous deletions in pancreatic carcinoma clustered at 18q22. Two of these deletions overlap with that found in HTB43 (Figure 3) (Hilgers et al., 1999) .
The extended screen of the homozygous deletion in HTB43 allowed the exclusion of various candidate genes on 18q21-18q22: the known tumor suppressor genes DCC, SMAD2 and SMAD4, the cluster of proteinase inhibitors (SerpinB5, B13, B3, B7, B10, B8) and the CIS-4 gene, a member of a family of proteins involved in negative regulation of cytokine signal transduction. Out of the four genes localized in the MCRL2 region, three are adhesion molecules that can possibly influence tumor progression, but all were selected for mutation screening (CDH7, CDH19, DNAM-1, FLJ23594). Two ESTs clusters: Hs.96900 and Hs.98628 were selected on the argument that they could be genuine genes (spliced ESTs and full length mRNAs) and on the basis of their putative functions. For each gene or cluster, transcription experiments were carried out by RT -PCR in eight cell lines and a total of 57 coding exons were analysed for point mutations by DHPLC in a series of 30 specimens. No somatic mutations were found. From these analyses candidate genes can be divided into two groups. The first one counts DNAM-1, CDH7, FLJ23594 and Hs.98628 for which neither transcript nor mutations could be evidenced. Therefore, there are no arguments in favor of their implication in head and neck cancer 18q22 deletions in head and neck cell carcinoma H Blons et al progression. The second counts CDH19 and Hs.96900 for which no mutations could be evidenced but transcription was retrieved in a subset of head and neck cancer cell lines. CDH19 seems to be expressed in various tissues including some of epithelial origin (Kools et al., 2000) . Localization of human cadherin genes has been related to regions exhibiting loss of heterozygosity as CDH16 at 8q22.1 in acute leukemia, CDH15 and CDH13 at 16q24.3 and 16q24 in breast cancer (Kremmidiotis et al., 1998) . The finding that CDH19 maps 18q22 and could be down-regulated in head and neck cancer cell lines, needs to be further characterized by studying CDH19 expression in tumor and non tumor tissues. Hs.969000 retained our attention as it demonstrated various expression patterns in head and neck cell lines. The characterization of the entire gene sequence led to the identification of a gene related to the cDNA recently cloned by Nagase et al. (2001) in a project of sequencing of large cDNAs. This cDNA was named KIAA1830. The sequence reported here was identical to KIAA1830 except for 30 bases that we added in the 5' untranslated region by Smart RACE PCR. We observed by Northern blot the presence of RNA for this gene in most of the tissues tested including trachea. The function of the protein is still unknown although analysis of protein database revealed the presence of a thioredoxin and a calsequestrin motif at the 5' end and a possible transmembrane domain of 22 AA at the 3' end from codon 375 -397. The presence of inactivating mutations constitutes an important argument for the identification of genes implicated in tumor suppression. However, in the absence of somatic mutations the differential transcription of CDH19 and KIAA1830 in HNSCC has to be interpreted cautiously and the implication of these genes in tumor progression can be investigated by studying promoter hypermethylation and by in vitro or in vivo tumorigenicity studies. Moreover, the concept of haploinsufficiency is arising in cancer research and has been demonstrated for a few genes such as p27 KIP1 in melanoma (Worm et al., 2000) or acute lymphoblastic leukemia (Komuro et al., 1999) . Demonstration of bi-allelic inactivation of genes is an approach that excludes the identification of genes requiring two functional copies to adequately suppress cell growth. Therefore we cannot exclude that gene dosage could play a role in head and neck cancer. Finally, this region counts a non-sequenced region of 400 Kb. It is therefore possible that undiscovered genes map within the gap. Our results confirm the existence of a region of deletion in 18q22 associated with tumor stage and provide the first data candidate genes study analysis within this region. 
Materials and methods
Specimens and DNA extraction
One hundred and forty-five patients with primary head and neck squamous cell carcinoma, attending the Department of Otolaryngology Head and Neck Surgery Laennec hospital in Paris, were recruited in a prospective study and informed consent was obtained with regards to French laws. Tumor tissues and blood samples were collected and stored as described previously (Blons et al., 1999a) . A pathologist (Franc¸oise Carnot) examined biopsies and estimated the percentage of tumor cells before DNA extraction. Tumors were located in the oral cavity (n=21, 15%), the oropharynx (n=59, 41%), the hypopharynx (n=34, 23%) and the larynx (n=31, 21%) and were grouped according to the TNM classification and staged as recommended by the American Joint Committee on Cancer (Sobin et al., 1988) . The initial tumor staging was stage I (n=6, 4%), stage II (n=31, 21%), stage III (n=28, 20%), stage IV (n=80, 55%).
Ten head and neck cell lines were used in the deletion screening study: HTB43, CCL-17, HSC-2, CRL2095, CRL1623, CRL1624, CRL1628, CRL1629 and CCL138 are available at the ATCC and CAL33 was a gift from Exonhit (Paris, France).
Tumor tissue DNAs were extracted after pulverization in liquid nitrogen and proteinase K digestion using standard methods (Blons et al., 1999a) . Lymphocyte and cell lines of DNAs were extracted using WIZARD extraction kit (Promega, Charbonnie`res, France).
Transcription levels were studied on eight out of the described head and neck cancer cell-lines; as for CRL1628 and CRL1624 no RNAs were available. Cell line RNAs were extracted using Rnable (Eurobio, Les Ulis, France) extraction kit according to the manufacturer's instructions.
Deletion mapping at chromosome 18
Analysis of allelic imbalance was performed with a PCR based approach using microsatellite typing. Markers and primers were selected by searching through the Marshfield genetic map (http:// research. marshfieldclinic.org / genetics /Map_Markers/ maps / IndexMapFrames. html), Genethon -CEPH genetic map (ftp: // ftp.genethon.fr / pub / Gmap / Nature-1995 / data/ data_chrom18) and Draft human genome browser (UC Santa Cruz April 1 2001, draft assembly of the human genome). The list of markers is shown on Figures 1 and 2 . LOH in tumors and extended homozygosity in cell lines were screened using 29 fluorescent markers and another 44 unlabeled markers were selected for the characterization of the homozygous deletion in HTB43. Three amplification protocols were developed using either AmpliTaq polymerase Cetus (Applied Biosystems, Courtaboeuf, France), AmpliTaq polymerase Gold (Applied Biosystems) and HotStarTaq TM polymerase (Quiagen, Les Ulis, France). PCR amplifications were run on a GeneAmp 1 PCR system 9700 (Applied Biosystems). Fluorescent markers were pooled in six different panels and analysed on Applied Biosystem ABI310 sequencer (Applied Biosystems). Details concerning individual marker amplification, panels and dilutions are available on request. Allelic imbalances (AI) were analysed by genotyper software (Applied Biosystems) with an automatic data-processing trace program described by Bluteau et al. (1999) and available on request. AI was defined for each tumor as a=(NL/NS)/(TL/TS) where L is the intensity of the larger allele and S, the intensity of the smaller allele in normal DNA (N) or tumor DNA (T). When a (loss of the small allele or 1/a (loss of the large allele) was inferior, the ratio of 40.5 LOH was ascertained. When the ratio ranged from 0.5 -0.7, it could be interpreted as the presence of contamination of tumor tissue by normal cells. To ascertain LOH in this group of tumors, we analysed three markers on 9p, a chromosome arm known to be lost in more than 90% of HNSCC. The AI 9p ratio was calculated for each tumor and used as control for interpretation of the AI 18q ratio. It allowed the identification of LOH at 18q when AI 18q was 4AI 9p . When AI 18q was superior to AI 9p allelic imbalance at 18q was considered as retention of heterozygosity. In four tumors, 9p showed extended homozygosity and no clear interpretation of 18q could be done. For these four cases, tumors were excluded of the definition of the regions of interest.
Homozygous deletion in cell lines was detected by the total absence of the PCR product from a given locus and confirmed by co-amplification of D18S61 with a positive control marker D18S462 of a larger size to protect it from the artifact due to DNA degradation as described in Yakicier et al. (2001) .
Gene identification and mutation screening
Known genes located in the region of deletion were identified by searching through the Draft human genome browser (genome.cse.ucsc.edu/goldenPath/apr2001
Tracks.html). Unknown genes were selected for mutation screening by several criteria: concordant results of genie gene prediction between Ensembl and Affymetrix databases, the existence of human spliced ESTs, degrees of conservation among species and putative protein function. Homozygous deletion for each selected gene was ascertained by an absence of amplification in HTB43 cell line and gene expression was tested in eight head and neck cell lines by RT -PCR. Reverse transcription was performed on 2 mg of total RNA using SuperScript TM II reverse transcriptase (Life Technologies, Cergy-Pontoise, France), 2/100 e of the cDNA mixtures were used as templates for specific gene amplifications.
The genomic sequences for candidate genes were retrieved using blast search (http://www.ncbi.nlm.nih.gov:80/BLAST/). Point mutations in the potential candidate genes were searched by Denaturing High Performance Liquid Chromatography (dHPLC) (Variant, Les Ulis, France) in the series of 10 HNSCC cell lines and in 20 tumors demonstrating LOH at 18q. All variant patterns were sequenced after purification with a QIAquick purification kit (Quiagen) using big dye terminator chemistry on an Applied Biosystems A310 sequencer (Applied Biosystems). All primers used for the determination of gene expression and gene mutation screenings are available on request.
Identification of Hs.96900 5' end by smart race PCR RNA extracted from CCL-17 served as a template for the determination of the entire cDNA sequence of the gene. Transcript 5' sequence was extended by Smart RACE PCR (Rapid Amplification of mRNA Ends by PCR, Clontech, Palo Alto, CA, USA) using one oligonucleotide primer derived from the 5' end of the known AK000800 EST belonging to the Hs.96900 EST cluster sequence: ACACGGTGTCTCTTCTGCATATGTTC.
Smart race products were first sequenced directly, and a 5' end fragment was amplified by nested PCR according to the manufacturer's instructions and cloned by TA cloning technology into pCR R 2.1 vector/INVaF'. INVaF' positive clones were selected by X-Gal and EcoR1 restriction patterns showing the expected size were sequenced on both ends with M13 and M13R universal primers. Hs.96900 expression studies in human tissues were performed using multiple Tissue Northern blot III 7767-1 (Clontech). Probe was obtained by amplification of CCL17 cDNA using one set of primers: AACATTTTGGATGGCA-CAGT, GCTCCTGCTGT-TCTTTGCTC followed by gel purification. Northern blot was hybridized with a [a-32P] dCTP-labeled 3'-end specific probe according to the manufacturer's instructions using a Megaprime labeling kit (Amersham, Les Ulis, France).
Transcriptional analysis of Hs.96900 EST cluster RT -PCRs, using different sets of primers on the Hs.96900 cluster, were run on head and neck cancer cell lines and cDNAs were available in the laboratory using the HotStarTaq TM polymerase protocol; set 1: (AAGCCCAAGGAGG-TGATAGC, GCTCCTGCTGTTCTTTGCTC); set 2 (CG-AACAAAAGATGATATTAT, TTTCATCTTTGAAAACA-AGCACA). Co-amplification was run using primer set 1 and an actin set of primers (GGCATGGGTCAGAAGGATT, AGGAAGGAAGGCTGGAAGAG) in the same conditions with a reduced number of cycles n=28.
Abbreviations HNSCC: head and neck cell carcinoma; MCRL: minimal common regions of loss; TSG: tumor suppressor gene
